Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection

Phase 4

Terminated

Brief Summary: Comparing two different corticosteroids (dexamethasone and triamcinolone) for use in sacroiliac joint injections

Detailed Description: Patients eligible for a sacroiliac joint injection will be randomized to receive one of two different steroids, dexamethasone or triamcinolone. The response immediately after injection will be assessed to confirm the diagnosis, and then they will be followed for three month to assess the degree of pain relief experienced

Recruitment & Eligibility

Inclusion Criteria

Aged >18, capable of understanding and providing consent in English, capable of complying with the outcome instruments used, capable of attending all planned follow up visits
Unilateral low back/buttocks pain of at least 2 weeks.
Patient reported 7 day average of numeric pain rating score (NPRS) low back/buttocks pain of at least 5/10 at baseline evaluation
Clinical diagnosis of sacroiliac joint pain as diagnosed by a board certified Physiatrist including history of low back/buttocks pain and at least 2 positive physical exam findings (including positive fortin finger sign, pain with palpation of posterior superior iliac spine, positive FABER's test, positive Gaenslan's test, positive sacral distraction, positive thigh thrust, positive lateral compression, positive sacral thrust)
Patient consents to sacroiliac joint corticosteroid injection in a shared decision-making process with the treating physician.
80% or more relief of index pain within first 5-15 minutes after injection

Exclusion Criteria

Clinical suspicion of alternative process is greater than clinical suspicion of sacroiliac joint pain
Those receiving remuneration for their pain treatment (e.g., disability, worker's compensation).
Those involved in active litigation relevant to their pain.
Those unable to read English and complete the assessment instruments.
Those unable to attend follow up appointments
The patient is incarcerated.
History of prior sacroiliac joint fusion
Progressive lower extremity neurologic deficit (from active radiculopathy, unhealed radiculopathy, or neuromuscular disease)
Sacroiliac joint steroid injection within the prior 12 months
2 Positive lumbar medial branch blocks within the past 12 months
Radiofrequency ablation of the lumbar spine within the past 12 months
Lumbar facet steroid injections within the past 12 months
Prior epidural steroid injection within the prior 3 months in any location within the spine.
Possible pregnancy or other reason that precludes the use of fluoroscopy.
Allergy to steroid, contrast media, or local anesthetics.
BMI>40.
Systemic inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, lupus).
Active infection or treatment of infection with antibiotics within the past 7 days.
Medical conditions causing significant functional disability (e.g., stroke, decompensated COPD, decompensated heart failure)
Chronic widespread pain or somatoform disorder (e.g. fibromyalgia).
Addictive behavior, severe clinical depression, or psychotic features.

Arm && Interventions

Group	Intervention	Description
Dexamethasone	Dexamethasone	dexamethasone injected into the sacroiliac joint
Triamcinolone	Triamcinolone Acetonide	triamcinolone injected into the sacroiliac joint

Primary Outcome Measures

Name	Time	Method
Pain Using Numeric Pain Rating Score	Baseline to 3 months; Average value at month 3 reported	Numeric pain rating score, 11 point scale (0-10) filled out on a form indicating the degree of relief/discomfort after the injection. Pain was assessed monthly from baseline to 3 months following the injection. The average value at month 3 is reported.

Secondary Outcome Measures